Skip to main content
SpringerLink
Log in

Efficacy of Signal Transduction Inhibition in Advanced Prostate Cancer

  • Chapter
  • First Online:
Prostate Cancer: Shifting from Morphology to Biology

  • 1141 Accesses

Abstract

The overall survival of patients with metastatic Castration-resistant Prostate Cancer (CRPC) is discouraging low (Attar et al., Clin Cancer Res 15:3251–3255, 2009).

CRPC exhibit tremendous heterogeneity and complexity, reflecting the dysregulation of multiple patterns, mutations, and pathways, combined in a different manner in each patient. Of course, the impact of this heterogeneity on outcome and response to therapy is tremendous. It is therefore an urgent need to identify the multiple cellular pathways cooperatively promoting progression of the single cases of CRPC for successfully therapeutically target them. Several molecular pathways have been implicated in prostate cancer progression from localized androgen-sensitive disease to lethal CRPC.

In this article, we will review some of the recent findings on signal transduction studies performed to identify novel targets and alternative chances of therapeutic intervention for advanced prostate cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Ang JE, Olmos D, de Bono JS (2009) CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer. Br J Cancer 100:671–675

    Article  PubMed  CAS  Google Scholar 

  • Antonarakis ES, Armstrong AJ (2011) Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 14(3):206–18, Epub 2011 May 17. Review

    Article  PubMed  CAS  Google Scholar 

  • Araujo J, Logothetis C (2009) Targeting Src signaling in metastatic bone disease. Int J Cancer 124:1–6

    Article  PubMed  CAS  Google Scholar 

  • Araujo J, Mathew P, Armstrong AJ et al (2009) Dasatinib and docetaxel combination treatment for patients with metastatic castration-resistant prostate cancer: analysis of study CA180–086 [abstract 7028]. Eur J Cancer 7:415S

    Google Scholar 

  • Attar RM, Takimoto CH, Gottardis MM (2009) Castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res 15:3251–3255

    Article  PubMed  CAS  Google Scholar 

  • Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M et al (2008) Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26:4563–4571

    Article  PubMed  CAS  Google Scholar 

  • Cairns P, Okami K, Halachmi S et al (1997) Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 57:4997–5000

    PubMed  CAS  Google Scholar 

  • Catz SD, Johnson JL (2003) BCL-2 in prostate cancer: a minireview. Apoptosis 8:29–37

    Article  PubMed  CAS  Google Scholar 

  • Cha E, Fong L (2011) Immunotherapy for prostate cancer: biology and therapeutic approaches. J Clin Oncol 29(27):3677–85

    Article  PubMed  CAS  Google Scholar 

  • Chang YM, Kung HJ, Evans CP (2007) Nonreceptor tyrosine kinases in prostate cancer. Neoplasia 9:90–100

    Article  PubMed  CAS  Google Scholar 

  • Chang YM, Bai L, Liu S et al (2008) Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene 27:6365–6375

    Article  PubMed  CAS  Google Scholar 

  • Chen CD, Welsbie DS, Tran C, Baek SH, Chen R et al (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10:33–39

    Article  PubMed  Google Scholar 

  • Chien Y et al (2011) Control of the senescence-associated secretory phenotype by NF-κB promotes senescence and enhances chemosensitivity. Genes Dev 25:2125–2136

    Article  PubMed  CAS  Google Scholar 

  • Chin KV, Yang WL, Ravatn R, Kita T, Reitman E et al (2002) Reinventing the wheel of cyclic AMP: novel mechanisms of cAMP signaling. Ann N Y Acad Sci 968:49–64

    Article  PubMed  CAS  Google Scholar 

  • Cho YS, Kim MK, Tan L, Srivastava R, Agrawal S et al (2002) Protein kinase A RIα antisense inhibition of PC3M prostate cancer cell growth: Bcl- 2 hyperphosphorylation, Bax up-regulation, and Bad-hypophosphorylation. Clin Cancer Res 8:607–614

    PubMed  CAS  Google Scholar 

  • Comstock CE, Knudsen KE (2007) The complex role of AR signaling after cytotoxic insult: implications for cell cycle based chemotherapeutics. Cell Cycle 6:1307–1313

    Article  PubMed  CAS  Google Scholar 

  • Cunha GR (2008) Mesenchymal-epithelial interactions: past, present, and future. Differentiation 76:578–586

    Article  PubMed  CAS  Google Scholar 

  • de Vries TJ, Mullender MG, van Duin MA et al (2009) The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts. Mol Cancer Res 7:476–488

    Article  PubMed  Google Scholar 

  • Edwards J, Bartlett JM (2005) The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: androgen-receptor cofactors and bypass pathways. BJU Int 95:1327–35

    Article  PubMed  CAS  Google Scholar 

  • Evans CP, Bai L, Kung H et al (2011) Effect of the specific Src kinase inhibitor AZD0530 on osteolytic lesions in prostate cancer [abstract 170]. Presented at the 2008 American Society of Clinical Oncology Genitourinary Cancers symposium, San Francisco, 14–16 Feb 2008. Available at: http://www.asco.org/ASCOv2/Meetings/Abstracts. Accessed 8 Feb 2011

  • Fizazi K (2007) The role of Src in prostate cancer. Ann Oncol 18:1765–1773

    Article  PubMed  CAS  Google Scholar 

  • Francis SH, Corbin JD (1999) Cyclic nucleotide-dependent protein kinases: intracellular receptors for cAMP and cGMP action. Crit Rev Clin Lab Sci 36:275–328

    Article  PubMed  CAS  Google Scholar 

  • Gao J, Arnold JT, Isaacs JT (2001) Conversion from a paracrine to an autocrine mechanism of androgen-stimulated growth during malignant transformation of prostatic epithelial cells. Cancer Res 61:5038–5044

    PubMed  CAS  Google Scholar 

  • Gerritsen WR, Sharma P (2012) Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapy. J Clin Immunol 32(1):25–35

    Article  PubMed  CAS  Google Scholar 

  • Grossmann ME, Huang H, Tindall DJ (2001) Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93:1687–1697

    Article  PubMed  CAS  Google Scholar 

  • Haag P, Bektic J, Bartsch G, Klocker H, Eder IE (2005) Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells. J Steroid Biochem Mol Biol 96:251–258

    Article  PubMed  CAS  Google Scholar 

  • Holzbeierlein J, Lal P, LaTulippe E, Smith A, Satagopan J et al (2004) Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 164:217–227

    Article  PubMed  CAS  Google Scholar 

  • Jiao J, Wang S, Qiao R et al (2007) Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Cancer Res 67:6083–6091

    Article  PubMed  CAS  Google Scholar 

  • Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, Godfrey WR (2010) Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 28(7):1099–105

    Article  PubMed  CAS  Google Scholar 

  • Kawata H, Ishikura N, Watanabe M, Nishimoto A, Tsunenari T et al (2010) Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity. Prostate 70:745–754

    Article  PubMed  CAS  Google Scholar 

  • Khor LY, Bae K, Al-Saleem T, Hammond EH, Grignon DJ et al (2008) Protein kinase A RI-α predicts for prostate cancer outcome: analysis of radiation therapy oncology group trial 86-10. Int J Radiat Oncol Biol Phys 71:1309–1315

    Article  PubMed  CAS  Google Scholar 

  • Kumari R (2012) Lighting up cancer studies. Drug Discov Devel 15(1):18

    Google Scholar 

  • Kung HJ, Evans CP (2009) Oncogenic activation of androgen receptor. Urol Oncol 27:48–52

    Article  PubMed  CAS  Google Scholar 

  • Li L, Ittmann MM, Ayala G, Tsai MJ, Amato RJ et al (2005) The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis 8:108–118

    Article  PubMed  CAS  Google Scholar 

  • Linja MJ, Savinainen KJ, Saramäki OR, Tammela TL, Vessella RL et al (2001) Amplification and overexpression of androgen receptor gene in hormonerefractory prostate cancer. Cancer Res 61:3550–3555

    PubMed  CAS  Google Scholar 

  • Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC et al (2008) Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res 68:6407–6415

    Article  PubMed  CAS  Google Scholar 

  • LoPiccolo J, Blumenthal GM, Bernstein WB et al (2008) Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 11:32–50

    Article  PubMed  CAS  Google Scholar 

  • Lubaroff DM (2012) Prostate cancer vaccines in clinical trials. Expert Rev Vaccines 11(7):857–868

    Article  PubMed  CAS  Google Scholar 

  • Malinowska K, Neuwirt H, Cavarretta IT, Bektic J, Steiner H et al (2009) Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr Relat Cancer 16:155–169

    Article  PubMed  CAS  Google Scholar 

  • Mayr B, Montminy M (2001) Transcriptional regulation by the phosphorylationdependent factor CREB. Nat Rev Mol Cell Biol 2:599–609

    Article  PubMed  CAS  Google Scholar 

  • McMenamin ME, Soung P, Perera S et al (1999) Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res 59:4291–4296

    PubMed  CAS  Google Scholar 

  • Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF et al (2008) Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68:4447–4454

    Article  PubMed  CAS  Google Scholar 

  • Morgan TM, Koreckij TD, Corey E (2009) Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr Cancer Drug Targets 9:237–249

    Article  PubMed  CAS  Google Scholar 

  • Nam S, Kim D, Cheng JQ et al (2005) Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 65:9185–9189

    Article  PubMed  CAS  Google Scholar 

  • Neary CL, Nesterova M, Cho YS, Cheadle C, Becker KG et al (2004) Protein kinase A isozyme switching: eliciting differential cAMP signaling and tumor reversion. Oncogene 23:8847–8856

    Article  PubMed  CAS  Google Scholar 

  • Nelson EC, Cambio AJ, Yang JC, Ok JH, Lara PN et al (2007) Clinical implications of neuroendocrine differentiation in prostate cancer. Prostate Cancer Prostatic Dis 10:6–14

    Article  PubMed  CAS  Google Scholar 

  • Sakamoto KM, Frank DA (2009) CREB in the pathophysiology of cancer: implications for targeting transcription factors for cancer therapy. Clin Cancer Res 15:2583–2587

    Article  PubMed  CAS  Google Scholar 

  • Sands WA, Palmer TM (2008) Regulating gene transcription in response to cyclic AMP elevation. Cell Signal 20:460–466

    Article  PubMed  CAS  Google Scholar 

  • Sarwar M, Persson JL (2011) The protein kinase A (PKA) intracellular pathway and androgen receptor: a novel mechanism underlying the castration-resistant and metastatic prostate cancer. J Cancer Sci Ther S5:003

    Google Scholar 

  • Scher HI, Sawyers CL (2005) Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23:8253–8261

    Article  PubMed  CAS  Google Scholar 

  • Schmitz M, Grignard G, Margue C et al (2007) Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis. Int J Cancer 120:1284–1292

    Article  PubMed  CAS  Google Scholar 

  • Shen MM, Abate-Shen C (2007) Pten inactivation and the emergence of androgenindependent prostate cancer. Cancer Res 67:6535–6538

    Article  PubMed  CAS  Google Scholar 

  • Sircar K, Yoshimoto M, Monzon FA et al (2009) PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol 218:505–513

    Article  PubMed  CAS  Google Scholar 

  • Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K et al (2010) Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest 120:2715–2730

    Article  PubMed  CAS  Google Scholar 

  • Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ, Small EJ, Cancer and Leukemia Group B Study 9663 (2003) Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 21(14):2673–2678

    Article  PubMed  CAS  Google Scholar 

  • Urbanucci A, Waltering KK, Suikki HE, Helenius MA, Visakorpi T (2008) Androgen regulation of the androgen receptor coregulators. BMC Cancer 8:219

    Article  PubMed  Google Scholar 

  • Vander Griend DJ, D’Antonio J, Gurel B, Antony L, Demarzo AM et al (2010) Cell-autonomous intracellular androgen receptor signaling drives the growth of human prostate cancer initiating cells. Prostate 70:90–99

    Article  PubMed  CAS  Google Scholar 

  • Vandyke K, Dewar AL, Farrugia AN et al (2009) Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis. Leukemia 23:994–997

    Article  PubMed  CAS  Google Scholar 

  • Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ et al (2009) Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res 69:8141–8149

    Article  PubMed  CAS  Google Scholar 

  • Wang Q, Li W, Zhang Y, Yuan X, Xu K et al (2009) Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138:245–256

    Article  PubMed  CAS  Google Scholar 

  • Wu D, Zhau HE, Huang WC, Iqbal S, Habib FK et al (2007) cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: implication in human prostate cancer bone metastasis. Oncogene 26:5070–5077

    Article  PubMed  CAS  Google Scholar 

  • Xiao X, Li BX, Mitton B, Ikeda A, Sakamoto KM (2010) Targeting CREB for cancer therapy: friend or foe. Curr Cancer Drug Targets 10:384–391

    Article  PubMed  CAS  Google Scholar 

  • Yang JC, Ok JH, Busby JE, Borowsky AD, Kung HJ, Evans CP (2009) Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer. Cancer Res 69(1):151–60

    Article  PubMed  CAS  Google Scholar 

  • Yoshimoto M, Cunha IW, Coudry RA et al (2007) FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 97:678–685

    Article  PubMed  CAS  Google Scholar 

  • Yu EY, Wilding G, Posadas E et al (2009) Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res 15:7421–7428

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Advanced Biomedical Sciences, Pathology Section, Faculty of Medicine and Surgery, University of Naples “Federico II”, via S. Pansini, n.5, 80131, Naples, Italy

    Stefania Staibano

Authors
  1. Stefania Staibano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefania Staibano .

Editor information

Editors and Affiliations

  1. Biomedical Advanced Sciences Pathology Section, University Federico II of Naples, Naples, Italy

    Stefania Staibano

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Staibano, S. (2013). Efficacy of Signal Transduction Inhibition in Advanced Prostate Cancer. In: Staibano, S. (eds) Prostate Cancer: Shifting from Morphology to Biology. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-7149-9_15

Download citation

Publish with us

Policies and ethics

Search

Navigation